Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Withdrawing FY2020 Financial Guidance Due to COVID-19 Pandemic

NEW YORK – Myriad Genetics announced on Wednesday morning that it is withdrawing its fiscal year 2020 financial guidance due to the impact of the COVID-19 pandemic.

Before mid-March, Myriad was experiencing test volume trends in line with its expectations, but starting late March and into its fiscal fourth quarter, social distancing guidelines began significantly impacting test volume trends, according to Bryan Riggsbee, the company's interim CEO and CFO. He didn't provide any further details on the magnitude of the impact.

When reporting its FY Q2 financials in early February, Myriad said it expected fiscal third quarter revenues of $172 million, EPS of $.30, and adjusted EPS of $.02. For full-year fiscal 2020, the firm had projected revenues of $735 million, EPS of $.80, and adjusted EPS of $.45. 

“Our priority as an organization during the coronavirus pandemic has been to maintain business continuity and access to testing, while ensuring the safety of our employees and customers," Riggsbee said in a statement. The company has stopped in-office sales calls and has transitioned to virtual sales, allowed non-essential personnel to work from home, facilitated at-home sample collection for patients, and implemented lab safety measures.

In early morning trading on the Nasdaq, Myriad's stock price was down around 4 percent at $14.23. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.